Search company, investor...
SkinMedica company logo


Founded Year



Acquired | Acquired

Total Raised




About SkinMedica

SkinMedica is focused on developing, acquiring, and commercializing products that improve the appearance of skin. SkinMedica markets and sells to physicians, with a focus on aesthetics, both prescription and non-prescription skin care products. The company's full line of aesthetic skin care products includes the revolutionary TNS Essential Serum and TNS Recovery Complex. The formulations in SkinMedica's clinical skin care collection enhance skin appearance, reduce signs of aging, and provide other skin care benefits. SkinMedica's primary prescription product, VANIQA (eflornithine hydrochloride) Cream 13.9%, is the only FDA-approved prescription product for the reduction of unwanted facial hair in women.In November 2012, SkinMedica was acquired by Allergan. The valuation of SkinMedica was undisclosed. Other terms of the deal were not released.

Headquarters Location

5909 Sea Lion Place Suite H

Carlsbad, California, 92010,

United States


Missing: SkinMedica's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: SkinMedica's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing SkinMedica

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

SkinMedica is included in 1 Expert Collection, including Beauty & Personal Care.


Beauty & Personal Care

2,067 items

Startups in the beauty & personal care space, including cosmetics brands, shaving startups, on-demand beauty services, salon management platforms, and more.

SkinMedica Patents

SkinMedica has filed 1 patent.

patents chart

Application Date

Grant Date


Related Topics




Stem cells, Transcription factors, Cell biology, Biotechnology, Developmental biology


Application Date


Grant Date



Related Topics

Stem cells, Transcription factors, Cell biology, Biotechnology, Developmental biology



Latest SkinMedica News

SkinMedica Frequently Asked Questions (FAQ)

  • When was SkinMedica founded?

    SkinMedica was founded in 1999.

  • Where is SkinMedica's headquarters?

    SkinMedica's headquarters is located at 5909 Sea Lion Place, Carlsbad.

  • What is SkinMedica's latest funding round?

    SkinMedica's latest funding round is Acquired.

  • How much did SkinMedica raise?

    SkinMedica raised a total of $105.6M.

  • Who are the investors of SkinMedica?

    Investors of SkinMedica include Allergan (acquired by Actavis), Domain Associates, Apax Partners, Montreux Equity Partners, Aisling Capital and 8 more.

  • Who are SkinMedica's competitors?

    Competitors of SkinMedica include OneSkin, Charleston Laboratories, Prosonix, Ikaria, Nanomed Pharmaceuticals and 13 more.

Compare SkinMedica to Competitors


Axcan is a specialty pharmaceutical company focused on the development and commercialization of drugs for diseases involving the digestive system.

Ikano Therapeutics

Ikano Therapeutics is a specialty pharmaceutical company focused on developing nasally delivered pharmaceutical products with a particular focus on drugs treating pain and disorders related to the central nervous system.

Sirion Holdings

Sirion Holdings is a specialty pharmaceutical company focused on ophthamology drugs

Tequesta Marine Biosciences

Tequesta Marine Biosciences is a specialty pharmaceutical firm that develops small molecule therepeutic drugs for inflammatory conditions.

Urigen Pharmacueticals

Urigen specializes in the design and commercialization of innovative products for patients with urological ailments. The company develops products for amelioration of Painful Bladder Syndrome (PBS), Urethritis, Nocturia and Over Active Bladder (OAB).

APT Therapeutics

APT Therapeutics develops acute-use drugs for controlling clot formation in stroke, pulmonary embolism, myocardial infarction, deep vein thrombosis, and transplantation.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.